Atrial fibrillation during hematopoietic stem cell transplantation: how often, why, and how we manage it - data from the ARCA-TPH registry

Clicks: 1
ID: 323349
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #175 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Atrial fibrillation (AF) is the most frequent cardiovascular (CV) complication during hematopoietic stem cell transplantation (HSCT), but data on its management in modern HSCT practice remain limited. Objectives To evaluate the incidence, risk factors, and management strategies of AF during hospitalization for HSCT and early post-discharge. Methods This single-centre, observational cohort study included 394 consecutive patients undergoing autologous or allogeneic HSCT between 2018 and 2022. Demographic, clinical, echocardiographic, and biochemical data were collected. Results AF or atrial flutter occurred in 18 patients (4.6%), with similar incidence in autologous (5%) and allogeneic (3.9%) HSCT. No significant differences were observed in baseline clinical or echocardiographic characteristics between patients with and without AF. Mean follow-up of patients developing AF was 3.4 years (SD 1.5 years). During hospitalization, AF was related to CV events such as heart failure (9 (50%) vs 19 (5.1%) patients; p<0.001) and non-CV complications notably acute lung disease (4 (22.2%) vs 16 (4.3%); p=0.009). Inpatient management was heterogeneous: among the 18 patients (4.6%) who developed AF, most (16 (88.9%)) were diagnosed in the first 12 hours from AF onset. Frequency control was the initial in-hospital strategy in 8 patients (44.4%) and rhythm control was preferred initially in 10 patients (55.6%). Anticoagulation decision at discharge was individualized due to comorbidities including thrombocytopenia, with 46.7% anticoagulated upon leaving the hospital. AF recurrence after discharge was uncommon (6.7%) and there were no cardioembolic complications. Among patients discharged without anticoagulation, no thromboembolic events occurred during follow-up, both in low-risk (CHA2DS2-VASc <2) and higher-risk groups. At discharge, all patients were in sinus rhythm, AF recurrence was low (6.7%), and antithrombotic strategies during follow-up were heterogeneous, with no adverse events observed (Figure 1). Conclusions AF represents a clinically significant early CV complication during HSCT hospitalization. Rhythm and antithrombotic strategies are heterogeneous. Rhythm control was not preferred initially in half of the patients due to the risk/limitations of anticoagulation in HSCT context, but no cardioembolic events after the episode occurred in either rhythm or frequency control in this registry. There is need for standardized, evidence-based protocols to optimize rhythm control and anticoagulation strategies in HSCT population.
Reference Key
openalex_W7172291521 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors I Gamez Guijarro, A Luna De Abia, N Fernandez Arias, J Ducay Rico, P Remior Perez, A Pardo Sanz, A Chinea Rodriguez, A Sanchez-Tornero De La Cruz, P Herrera Puente, F J Lopez Jimenez, J L Zamorano Gomez, P Agudo Quilez
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.190
URL
https://doi.org/10.1093/eurheartjsupp/suag097.190
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.